✦ Free Shipping Over $75 ✦
Start with the umbrella term
A cannabinoid is a signaling compound, not a synonym for CBD
The word cannabinoid describes a broad group of compounds associated with the body’s endocannabinoid system. The best-known examples, delta-9 THC and CBD, come from Cannabis sativa. Researchers have identified more than 100 other phytocannabinoids, including CBG, CBN, CBC and THCV.
The body also makes its own cannabinoid-like messengers. Laboratories create additional compounds for research, approved medicines and, in a very different category, unregulated intoxicating products. These groups can share receptor targets without sharing the same strength, safety profile or effect.
Cannabinoid is a family name that covers compounds from plants, the body and laboratories.
It does not mean every cannabinoid is intoxicating, sedating or interchangeable with THC.
A product can contain one cannabinoid or a combination. Its real-world effect depends on the exact compounds, amounts, route, other ingredients and the person using it.
Origin creates three main categories
Phytocannabinoids, endocannabinoids and synthetic cannabinoids
| Family | Where it comes from | Examples | What to remember |
|---|---|---|---|
| Phytocannabinoids | Cannabis and hemp plants | CBD, THC, CBG, CBN, CBC | Plant compounds differ substantially in receptor activity and evidence. |
| Endocannabinoids | Made by the human body | Anandamide, 2-AG | Short-lived messengers help regulate internal signaling. |
| Synthetic cannabinoids | Made in laboratories | Dronabinol, nabilone and many research compounds | Approved medicines and illicit high-potency products must not be treated as one category. |
“Synthetic cannabinoid” needs care. Dronabinol and nabilone are regulated prescription medicines with defined ingredients and approved uses. Illicit products sometimes sold as Spice or K2 can contain potent, unpredictable receptor agonists and are not equivalents of CBD oil or hemp extract.
Likewise, hemp is a legal plant classification tied to delta-9 THC concentration under federal law. It is not a guarantee that every hemp-derived finished product is non-intoxicating, accurately labeled or lawful in every jurisdiction.
The body already has a cannabinoid network
The endocannabinoid system includes messengers, receptors and enzymes
The endocannabinoid system is a distributed signaling network. The body produces endocannabinoids when needed, they interact with receptors and enzymes then break them down. This on-demand pattern differs from taking a plant-derived cannabinoid that enters from outside the body.
Concentrated in the central nervous system but also present elsewhere. Strong CB1 activation is central to THC intoxication.
Commonly discussed in immune and peripheral tissues, although their distribution and roles are more complex than a single location.
Two major endocannabinoid messengers with different synthesis, breakdown and receptor patterns.
FAAH and MAGL are among the enzymes that help terminate endocannabinoid signaling.
Cannabinoid biology is not limited to CB1 and CB2. CBD, CBG and other compounds can influence serotonin receptors, transient receptor potential channels, enzymes and other targets. A label that lists two cannabinoids does not tell you the whole mechanism, but it is the necessary starting point.
The two best-known plant cannabinoids
CBD and THC have similar origins but very different profiles
Delta-9 THC is a partial agonist at CB1 and CB2 receptors and is primarily responsible for cannabis intoxication. The amount, route and individual tolerance all change the experience. THC also creates impairment and drug-testing concerns that do not disappear simply because a product came from hemp.
CBD is generally not considered intoxicating and has low direct affinity for CB1 and CB2. It influences a wider set of targets and can modify some cannabinoid signaling. Evidence is strongest for a purified prescription CBD medicine used for specific seizure disorders. Consumer CBD products are not equivalent to that medicine in amount, formulation, oversight or intended use.
| Feature | CBD | Delta-9 THC |
|---|---|---|
| Typical intoxication | Not generally intoxicating | Intoxicating and potentially impairing |
| Primary receptor relationship | Low direct CB1/CB2 affinity with several other targets | Partial CB1 and CB2 agonist |
| Drug-test relevance | Not the standard target, but products may contain THC | Metabolites are the usual target of cannabis tests |
| Approved U.S. drug example | Purified CBD in Epidiolex | Dronabinol medicines use synthetic delta-9 THC |
For a focused explanation, read what CBD is and Mood’s guide to how CBD works.
Minor refers to abundance, not importance
CBG, CBN, CBC and other emerging cannabinoids
Minor cannabinoids usually appear in lower concentrations than CBD or THC in the plant. Interest is growing quickly, but human evidence is generally smaller and less mature. A plausible laboratory mechanism should not be presented as a proven consumer outcome.
| Cannabinoid | Full name | Useful distinction |
|---|---|---|
| CBG | Cannabigerol | Often called a precursor cannabinoid because its acidic form contributes to several cannabinoid pathways in the plant. |
| CBN | Cannabinol | Forms partly as THC oxidizes over time and is widely marketed in nighttime products, though sleep evidence remains developing. |
| CBC | Cannabichromene | Non-intoxicating in ordinary descriptions, with research still dominated by preclinical work. |
| THCV | Tetrahydrocannabivarin | Structurally related to THC but with dose-dependent receptor behavior and limited clinical evidence. |
| CBDV | Cannabidivarin | A CBD-related compound under investigation, not a substitute term for CBD. |
CBG, CBN and CBC should not inherit every claim made about CBD. Each needs its own human research, serving context and safety assessment. See Mood’s dedicated guides to CBG gummies and CBN gummies for format-specific detail.
One family, different jobs
Compare cannabinoids by effect, evidence and product context
No single ranking tells you which cannabinoid is “best.” A useful comparison begins with the intended experience, whether intoxication must be avoided, the strength of human evidence and the other ingredients in the product.
| Cannabinoid | Intoxicating potential | Research maturity | Common retail context |
|---|---|---|---|
| CBD | Generally non-intoxicating | Most studied of the consumer hemp cannabinoids | Oils, gummies, topicals and vapes |
| Delta-9 THC | Intoxicating | Substantial research, with benefits and risks depending on use | Regulated cannabis and some hemp-derived products |
| CBG | Not generally considered intoxicating | Growing but still limited human evidence | Focus-oriented oils and gummies |
| CBN | Much weaker central effects than THC, but not evidence-free | Small number of newer sleep trials | Nighttime oils and gummies |
| CBC | Not generally considered intoxicating | Mostly preclinical | Multi-cannabinoid extracts |
The comparison changes again when several cannabinoids appear together. Mood’s CBD versus CBG versus CBN guide goes deeper into those three consumer categories without treating them as interchangeable.
The extract label tells you what stayed in
Full-spectrum, broad-spectrum and isolate describe composition
A CBD isolate product aims to contain CBD without other cannabinoids. Broad-spectrum products generally contain multiple plant compounds while attempting to remove THC. Full-spectrum products retain a wider range of cannabinoids and can contain lawful trace THC.
These terms do not automatically prove quality, effectiveness or the exact amount of any ingredient. They describe an intended composition that still needs confirmation from the serving panel and batch report.
Useful when a single cannabinoid is preferred, but it does not guarantee zero testing or interaction risk.
Multiple plant compounds with THC removed or minimized, depending on the product and test sensitivity.
A wider cannabinoid profile including possible trace THC, which matters for sensitivity and drug tests.
Read the full explanation in Mood’s entourage-effect and extract guide.
Translate the package into a real serving
How to read a cannabinoid product label
1
Find every named cannabinoid
Look for CBD, CBG, CBN, delta-9 THC and any other active cannabinoid.
2
Convert the container total
A 1,000 mg bottle is not a 1,000 mg serving. Use the serving size and number of servings.
3
Check extract type
Full-spectrum, broad-spectrum and isolate change the expected profile and THC question.
4
Read other actives
Melatonin, mushrooms, caffeine and botanicals can shape the experience.
5
Match the batch
The certificate of analysis should correspond to the product and lot in hand.
6
Review warnings and context
Medication, driving, pregnancy and testing concerns require more than the marketing panel.
For a purchase-focused checklist, use Mood’s CBD buyer’s guide.
Identity comes before benefit
Quality testing should confirm cannabinoids and screen contaminants
A certificate of analysis should identify the tested cannabinoid profile and, when included, contaminant results such as heavy metals, pesticides, microbes and residual solvents. The method, laboratory, date and sample or lot identifier help show whether the report is meaningful.
Labels can differ from test results, and one batch does not prove every future batch. Use Mood’s lab-results library to match the current product where available.
Do not confuse precision with proof
A detailed milligram number confirms what the label claims to contain. It does not prove every marketed benefit. Ingredient identity, product quality and clinical effect are separate questions.
Choose the context before the compound
Match the cannabinoid product to your goal, routine and constraints
Start with the practical question. Is the product intended for a daytime routine, evening wind-down, portability or a measured oil format? Must THC be avoided for driving, sensitivity or workplace testing? Are prescriptions involved? The answer can narrow the format and extract before comparing brand language.
Introduce one formula at a time and keep the serving stable long enough to observe a pattern. Do not increase a serving simply because an oral product feels delayed. Mood’s CBD dosage guide explains why body size alone cannot determine a universal serving.
Bring the exact label and batch report to a pharmacist when medicines are involved. CBD and other cannabinoids can affect drug metabolism, and sedating ingredients can add together. The cannabinoid interaction guide provides a preparation checklist.
Quick answers
Frequently asked questions about cannabinoids
Are all cannabinoids from cannabis?
No. Phytocannabinoids come from cannabis, endocannabinoids are made by the body and synthetic cannabinoids are created in laboratories.
Do all cannabinoids make you high?
No. Delta-9 THC is intoxicating, while CBD and CBG are generally not. Individual compounds and finished products still require separate evaluation.
How many cannabinoids are in cannabis?
More than 100 phytocannabinoids have been identified, while estimates vary with classification and analytical methods.
Is CBD a cannabinoid?
Yes. CBD, or cannabidiol, is one of the best-known phytocannabinoids.
What is the difference between cannabinoids and terpenes?
Cannabinoids and terpenes are different chemical families. Terpenes contribute aroma and may have biological activity, but they are not cannabinoids.
What are endocannabinoids?
They are short-lived signaling molecules produced by the body. Anandamide and 2-AG are two major examples.
Is CBN just old THC?
CBN can form as THC oxidizes, but it is a distinct compound with its own pharmacology and developing research base.
Can a cannabinoid product cause a positive drug test?
Products containing THC can. CBD, CBG and CBN are not the usual targets, but full-spectrum formulas and mislabeled products can expose users to THC.
Evidence and transparency
Sources and editorial review
Research method: This guide prioritizes U.S. government health resources and peer-reviewed reviews for definitions, cannabinoid families and endocannabinoid-system biology. Product examples are used to teach label interpretation, not to transfer research findings from one cannabinoid to another.
- NCCIH. Cannabis, Marijuana and Cannabinoids: What You Need to Know.
- FDA. Products Containing Cannabis or Cannabis-Derived Compounds.
- Murray CH et al. The Development of Cannabinoids as Therapeutic Agents in the United States. 2024.
- Pereira M et al. Phytocannabinoids and Synthetic Cannabinoids: A Review. 2024.
- Nachnani R et al. Minor Cannabinoids: Biosynthesis, Pharmacology and Potential Uses. 2021.
- FDA. Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research.
General educational information, not medical or legal advice. Cannabinoid research and state rules continue to develop, and finished-product composition varies.
Written by Mood Editorial TeamMaterially researched and updated September 1, 2026. No physician, pharmacologist or attorney review is claimed. Corrections can be submitted through Mood Wellness support.
